At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridge based CFO’ operating in the Biotechnology space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Chief Financial Officer of Eagle Genomics
Gavin is a Chartered Accountant with 15 years’ experience managing the varied financial operations of rapidly growing technology businesses. Gavin qualified with PwC in London before moving into the high technology sector and has worked extensively both in the UK and overseas. He has been involved with many companies during intense periods of both organic and acquisitive expansion. His most recent appointment was at AIM listed Brady plc during a time when the group went through a period of rapid revenue growth and geographic expansion including the integration of multiple significant acquisitions. The group also secured a substantial and significantly oversubscribed share placing. He has a BSc in Software Engineering from Durham University.
Follow Gavin Horn:
About Eagle Genomics: Eagle Genomics is a enterprise software solutions company to enable the management, orchestration and exploitation of life sciences data.
Chairman of the Board, CEO, CFO, CSO & Co-Founder of PixarBio
Follow Frank Reynolds:
About PixarBio: PixarBio Corp is a specialty Biotechnology company focused on pre-clinical and commercial development of new products.
Chief Financial Officer of Congenica
Wendy Britten is a Senior Finance professional with an extensive track record of delivering in leadership positions across a range of industries, including numerous M&A transactions. Most recently Wendy headed up the Group Finance Business Performance team at AstraZeneca, working in close partnership with the CEO, CFO and the Senior Executive Team. Prior to joining AZ Wendy progressed her career in a variety of roles with PricewaterhouseCoopers, starting in Audit and culminating as a Director in M&A in London and New York. Wendy holds a BSc in Mathematics from University of Sheffield and is a qualified Chartered Accountant.
Follow Wendy Britten:
About Congenica: Congenica is a biotechnology company that provides a diagnostic decision support platform.
President & CFO of Nivien Therapeutics
Follow Nikita Shah:
About General Biotechnologies, Nivien Therapeutics: Nivien Therapeutics is developing the first small molecule drugs to enhance both chemo and immunotherapies.
CFO of Crescendo Biologics
Theodora Harold is a chartered accountant with significant experience as a Chief Financal Officer and Company Secretary with early stage and growing companies in the biotech sector. She has a background in both industry and corporate finance with 16 years of experience in SMEs in the biotech and hi-tech sectors and has held roles with Cytomyx Holdings plc, RioTech Pharmaceuticals Ltd, OrthoMimetics Ltd, Hybrid Biosystems Ltd, Myotec Therapeutics Ltd and Mission Therapeutics Ltd. Prior to this, Theodora trained with PricewaterhouseCoopers and read Classics at Trinity College, Cambridge.
Follow Theo Harold:
About Crescendo Biologics, Crescendo Biologics, Crescendo Biologics: Crescendo Biologics is engaged in the development of a proprietary drug portfolio based on their VH antibody fragment platform.
Chief Financial Officer of Horizon Discovery
Richard has over 15 years’ experience as a chartered accountant, working with life science companies from start-ups to global pharmaceuticals. He also has a first class degree in biological sciences from Durham University. Past roles include Vice President, Finance at CSR plc, a listed hi-tech company with revenues of $1bn. During his time at CSR Richard had worldwide responsibility for finance, making significant contributions to the transformational acquisition and integration of a NASDAQ listed Zoran Corp., product portfolio management, R&D budgeting and business investment / divestment decisions. Before this, Richard was a Director in Deloitte’s life sciences practice, where he specialized in capital market transactions including IPOs, M&A and fundraising on both the UK and the US markets. Beyond his corporate responsibilities, Richard has advised the EC on funding for life science companies and presented at investor conferences and technical seminars on financial issues facing the life science industry.
Follow Richard Vellacott:
About Horizon Discovery: Horizon is a gene editing company that designs & engineers genetically-modified cells, applying them to advance human health.
Manmeet S. Soni
Chief Financial Officer of Reata Pharmaceuticals
CFO/EVP at Reata Pharmaceuticals.
Follow Manmeet S. Soni:
About Reata Pharmaceuticals, Reata Pharmaceuticals: Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Chief Financial Officer of Vor Biopharma
Nathan Jorgensen is the Chief Financial Officer at Vor Biopharma.
Follow Nathan Jorgensen:
About Vor Biopharma: Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
CFO of Seres Therapeutics
Eric Shaff has over 15 years of experience working in leadership roles in biotechnology finance, corporate development, and capital markets. He serves as the executive vice president and chief financial officer of [Seres Therapeutics](https://www.crunchbase.com/organization/seres-health#/entity), a therapeutics company engaged in the R&D of drugs for the treatment of microbiome diseases. Previously, Shaff was vice president of corporate finance at Momenta Pharmaceuticals, where he helped manage Momenta Pharmaceutical’s accounting, finance, planning, and procurement functions as well as contributing to Momenta Pharmaceutical’s investor relations efforts. Prior to joining Momenta Pharmaceuticals, he was the vice president of finance at Genzyme’s Rare Genetic Disease Division. Shaff held several positions in business unit finance, corporate finance, and corporate development at Genzyme. Before joining Genzyme, he worked in corporate finance at Pfizer and worked in investment banking for Broadview International. Shaff obtained his bachelor’s degree in political science and economics from the University of Pennsylvania and his MBA in finance from the Johnson Graduate School of Management at Cornell University.
Follow Eric Shaff:
About Seres Therapeutics: Seres Therapeutics is a microbiome therapeutics company focused on discovering and developing Ecobiotic therapeutic products.
Co-founder, Director and CFO of Nuclera
A molecular biologist by trade, Jiahao has coordinated multi-national collaborative projects and experienced first hand the limitations of the current provision of DNA. This intimate knowledge of user requirements enables him to guide Nuclera’s commercial operations towards creating the right product for the right market. Jiahao holds a BSc from the University of California, Berkeley, and a PhD in Molecular Biology from the University of Cambridge.
Follow Jiahao Huang:
About Nuclera: Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis.